

Comparison of HCC incidence between entecavir and tenofovir

Table S1. Univariate and multivariate analyses of on-treatment factors at month 12 associated with hepatocellular carcinoma in patients treated with entecavir or TDF

Parameters	Univariate Analysis			Multivariate Analysis		
	HR	95% CI	p Value	HR	95% CI	p Value
TDF vs. entecavir	0.585	0.425-0.806	0.001	0.567	0.412-0.837	0.003
ALT normalization at month 12	0.742	0.562-0.978	0.034	0.738	0.551-0.990	0.042
Undetectable HBV DNA at month 12	0.737	0.509-1.068	0.107			
FIB-4 at month 12	1.042	1.031-1.054	< 0.001	1.093	1.074-1.113	< 0.001
AFP at month 12	1.013	1.010-10.16	< 0.001	1.012	1.009-1.115	< 0.001

AFP, alpha-fetoprotein; ALT, alanine aminotransferase; CI, confidence interval; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HR, hazard ratio; TDF, tenofovir disoproxil fumarate.

Table S2. Univariate and multivariate analyses of factors associated with hepatocellular carcinoma in NA-naive patients (*n* = 1353)

Variables	Univariate Analysis		Multivariate Analysis	
	Hazard ratio (95% CI)	p Value	Hazard ratio (95% CI)	p Value
Age (year)	1.037 (1.025-1.049)	< 0.001	1.041 (1.028-1.053)	< 0.001
Sex, male vs. female	1.192 (0.865-1.644)	0.283	1.553 (1.119-2.156)	0.008
HBeAg, positive vs. negative	1.055 (0.763-1.457)	0.747		
Decompensation, yes vs. no	2.252 (1.631-3.109)	< 0.001	1.626 (1.058-2.499)	0.027
TDF vs. entecavir	0.523 (0.363-0.752)	0.005	0.582 (0.401-0.843)	0.004
Diabetes mellitus, yes vs. no	1.695 (1.254-2.290)	0.006	1.487 (1.099-2.013)	0.010
Hypertension, yes vs. no	1.665 (1.254-2.211)	0.004		
HBV DNA, per log ₁₀ IU/mL	1.000 (0.909-1.000)	0.997		
AST, per U/L	1.000 (0.999-1.001)	0.598		
ALT, per U/L	1.000 (0.999-1.000)	0.253		
Total bilirubin, per mg/dL	0.989 (0.943-1.037)	0.639		
Albumin, per g/L	0.550 (0.448-0.675)	< 0.001	0.765 (0.583-1.004)	0.053
INR, per ratio	1.301 (0.829-2.042)	0.253		
eGFR, mL/min/1.73 m ²	0.991 (0.986-0.996)	< 0.001		
Platelet, per 10 ³ /μL	0.993 (0.991-0.996)	< 0.001	0.997 (0.994-1.000)	0.031
AFP at baseline, per ng/mL	1.000 (0.999-1.001)	0.826		
Child-Pugh score	1.162 (1.078-1.253)	< 0.001		
FIB-4	1.051 (1.033-1.069)	< 0.001		
APRI	1.004 (0.985-1.023)	0.701		

AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.

Comparison of HCC incidence between entecavir and tenofovir

Table S3. Univariate and multivariate analyses of factors associated with hepatocellular carcinoma in patients with compensated cirrhosis at baseline (*n* = 1320)

Variables	Univariate Analysis		Multivariate Analysis	
	Hazard ratio (95% CI)	<i>p</i> Value	Hazard ratio (95% CI)	<i>p</i> Value
Age (year)	1.033 (1.020-1.045)	< 0.001	1.033 (1.020-1.047)	< 0.001
Sex, male vs. female	1.253 (0.882-1.780)	0.208	1.461 (1.017-2.097)	0.040
HBeAg, positive vs. negative	1.207 (0.864-1.686)	0.270		
NA-naïve, yes vs. no	0.982 (0.648-1.488)	0.931		
TDF vs. entecavir	0.628 (0.438-0.900)	0.011	0.689 (0.475-0.999)	0.049
Diabetes mellitus, yes vs. no	1.554 (1.120-2.156)	0.008	1.340 (0.960-1.871)	0.086
Hypertension, yes vs. no	1.751 (1.300-2.358)	< 0.001		
HBV DNA, per log ₁₀ IU/mL	1.030 (0.933-1.137)	0.560		
AST, per U/L	1.000 (0.998-1.001)	0.555		
ALT, per U/L	1.000 (0.999-1.000)	0.326		
Total bilirubin, per mg/dL	1.011 (0.913-1.118)	0.838		
Albumin, per g/L	0.573 (0.433-0.758)	< 0.001	0.658 (0.495-0.874)	0.004
INR, per ratio	1.362 (0.773-2.400)	0.286		
eGFR, mL/min/1.73 m ²	0.990 (0.985-0.995)	< 0.001	0.994 (0.989-1.000)	0.039
Platelet, per 10 ³ /μL	0.995 (0.992-0.998)	0.001		
AFP at baseline, per ng/mL	1.000 (0.997-1.002)	0.720		
Child-Pugh score	1.264 (1.055-1.515)	0.011		
FIB-4	1.059 (1.033-1.086)	< 0.001		
APRI	1.010 (0.976-1.046)	0.566		

AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.

Table S4. Univariate and multivariate analyses of factors associated with hepatocellular carcinoma in NA-naïve patients with compensated cirrhosis at baseline (*n* = 1153)

Variables	Univariate analysis		Multivariate analysis	
	Hazard ratio (95% CI)	<i>p</i> value	Hazard ratio (95% CI)	<i>p</i> value
Age (year)	1.033 (1.019-1.046)	< 0.001	1.030 (1.016-1.045)	< 0.001
Sex, male vs. female	1.219 (0.843-1.762)	0.293	1.474 (1.008-2.154)	0.045
HBeAg, positive vs. negative	1.160 (0.808-1.666)	0.422		
TDF vs. entecavir	0.534 (0.355-0.805)	0.003	0.576 (0.379-0.877)	0.010
Diabetes mellitus, yes vs. no	1.604 (1.129-2.279)	0.008	1.428 (1.003-2.035)	0.048
Hypertension, yes vs. no	1.879 (1.366-2.583)	< 0.001		
HBV DNA, per log ₁₀ IU/mL	1.016 (0.909-1.136)	0.774		
AST, per U/L	1.000 (0.998-1.001)	0.673		
ALT, per U/L	0.999 (0.998-1.001)	0.359		
Total bilirubin, per mg/dL	1.008 (0.904-1.123)	0.887		
Albumin, per g/L	0.584 (0.430-0.794)	<0.001	0.671 (0.493-0.914)	0.011
INR, per ratio	1.199 (0.609-2.364)	0.599		
eGFR, mL/min/1.73 m ²	0.990 (0.984-0.995)	< 0.001	0.995 (0.989-1.001)	0.075
Platelet, per 10 ³ /μL	0.995 (0.992-0.998)	0.003		
AFP at baseline, per ng/mL	1.000 (0.997-1.002)	0.720		
Child-Pugh score	1.234 (1.013-1.504)	0.037		
FIB-4	1.059 (1.032-1.087)	< 0.001		

Comparison of HCC incidence between entecavir and tenofovir

APRI 1.013 (0.973-1.054) 0.529

AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.

Table S5. Univariate and multivariate analyses of factors associated with hepatocellular carcinoma in patients enrolled after 2011 (*n* = 1162)

Variables	Univariate analysis		Multivariate analysis	
	Hazard ratio (95% CI)	<i>p</i> value	Hazard ratio (95% CI)	<i>p</i> value
Age (year)	1.037 (1.022-1.052)	< 0.001	1.034 (1.019-1.049)	< 0.001
Sex, male vs. female	1.607 (1.029-2.508)	0.037	1.902 (1.212-2.983)	0.005
HBeAg, positive vs. negative	0.907 (0.589-1.397)	0.657		
Decompensation, yes vs. no	0.717 (0.499-1.030)	0.072		
NA-naïve, yes vs. no	1.752 (1.193-2.573)	0.004		
TDF vs. entecavir	1.987 (1.392-2.837)	< 0.001		
Diabetes mellitus, yes vs. no	1.156 (1.026-1.303)	0.018	1.593 (1.082-2.345)	0.018
Hypertension, yes vs. no	1.000 (0.999-1.001)	0.813		
HBV DNA, per log ₁₀ IU/mL	1.000 (0.999-1.000)	0.534		
AST, per U/L	1.009 (0.957-1.064)	0.738		
ALT, per U/L	0.521 (0.405-0.671)	< 0.001		
Total bilirubin, per mg/dL	1.558 (0.938-2.588)	0.087		
Albumin, per g/L	0.987 (0.981-0.993)	< 0.001	0.543 (0.421-0.699)	< 0.001
INR, per ratio	0.994 (0.990-0.997)	< 0.001		
eGFR, mL/min/1.73 m ²	0.999 (0.998-1.001)	0.589		
Platelet, per 10 ³ /μL	1.207 (1.095-1.330)	< 0.001		
AFP at baseline, per ng/mL	1.049 (1.023-1.076)	< 0.001		
Child-Pugh score	1.005 (0.981-1.029)	0.707		
FIB-4	1.037 (1.022-1.052)	< 0.001		
APRI	1.607 (1.029-2.508)	0.037		

AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.

Comparison of HCC incidence between entecavir and tenofovir

Table S6. Baseline characteristics of all patients adjusted by propensity score matching or inverse probability of treatment weighting

Variables	Propensity score matching			Inverse probability of treatment weighting		
	Entecavir <i>n</i> = 545	TDF <i>n</i> = 545	<i>p</i> value	Entecavir <i>n</i> = 994	TDF <i>n</i> = 567	<i>p</i> value
Age (year)	54.3 ± 11.8	54.5 ± 12.9	0.718	54.9 ± 11.8	55.0 ± 12.9	0.839
Sex, male	414 (78.0%)	411 (75.4%)	0.832	73.8%	74.0%	0.919
HBeAg-positive status	129 (23.6%)	125 (22.9%)	0.774	22.2%	22.9%	0.742
Decompensation status	55 (10.1%)	57 (10.5%)	0.842	16.3%	15.7%	0.766
NA-naïve	468 (85.9%)	462 (84.8%)	0.608	86.5%	86.9%	0.821
Diabetes mellitus, yes	83 (15.2%)	86 (15.8%)	0.802	20.7%	21.6%	0.675
Hypertension, yes	137 (25.1%)	127 (23.3%)	0.480	26.2%	25.6%	0.792
HBV DNA, log ₁₀ IU/mL	5.36 ± 1.44	5.37 ± 1.43	0.896	5.43 ± 1.49	5.36 ± 1.44	0.376
AST, U/L	109.2 ± 221.4	112.7 ± 264.1	0.810	123.0 ± 247.6	133.1 ± 287.3	0.479
ALT, U/L	140.6 ± 285.1	149.6 ± 382.8	0.659	153.4 ± 332.8	154.2 ± 349.9	0.964
Total bilirubin, mg/dL	1.68 ± 3.03	1.58 ± 2.90	0.583	1.89 ± 3.45	1.86 ± 3.37	0.831
Albumin, g/dL	4.06 ± 0.58	4.07 ± 0.57	0.773	3.96 ± 0.63	3.94 ± 0.64	0.529
INR	1.17 ± 0.26	1.16 ± 0.23	0.745	1.19 ± 0.27	1.20 ± 0.28	0.323
eGFR, mL/min/1.73 m ²	93.8 ± 26.9	94.9 ± 28.3	0.516	89.6 ± 31.1	88.62 ± 42.0	0.626
Platelet, ×10 ³ /μL	147.1 ± 53.7	147.9 ± 54.0	0.804	138.7 ± 58.0	137.49 ± 57.0	0.680
AFP, ng/mL	24.8 ± 73.3	30.8 ± 112.	0.297	33.6 ± 145.9	33.8 ± 111.9	0.967
Child-Pugh score	5.54 ± 1.27	5.49 ± 1.19	0.508	5.79 ± 1.50	5.78 ± 1.56	0.896
FIB-4	3.77 ± 3.45	3.70 ± 3.76	0.771	4.62 ± 4.82	4.82 ± 5.57	0.470
APRI	2.43 ± 5.79	2.60 ± 6.62	0.642	2.98 ± 6.16	3.39 ± 7.66	0.279

AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.

Table S7. Baseline characteristics of patients with compensated cirrhosis adjusted by propensity score matching or inverse probability of treatment weighting

Variables	Propensity score matching			Inverse probability of treatment weighting		
	Entecavir <i>n</i> = 481	TDF <i>n</i> = 481	<i>p</i> value	Entecavir <i>n</i> = 811	TDF <i>n</i> = 509	<i>p</i> value
Age (year)	55.1 ± 11.7	54.8 ± 13.1	0.791	55.3 ± 11.5	55.2 ± 13.2	0.900
Sex, male	350 (72.7%)	354 (73.6%)	0.771	73.0%	73.5%	0.826
HBeAg-positive status	112 (23.3%)	108 (22.4%)	0.759	22.2%	23.4%	0.600
NA-naïve	416 (86.4%)	421 (87.5%)	0.632	87.4%	87.4%	0.966
Diabetes mellitus, yes	75 (15.6%)	76 (15.8%)	0.929	20.2%	21.5%	0.579
Hypertension, yes	116 (24.1%)	115 (23.9%)	0.940	26.7%	26.1%	0.830
HBV DNA, log ₁₀ IU/mL	5.41 ± 1.43	5.37 ± 1.42	0.677	5.43 ± 1.45	5.37 ± 1.44	0.459
AST, U/L	81.0 ± 129.1	74.9 ± 129.8	0.469	85.4 ± 140.5	96.8 ± 185.7	0.233
ALT, U/L	104.0 ± 164.5	103.4 ± 244.9	0.962	109.4 ± 173.0	116.0 ± 263.3	0.617
Total bilirubin, mg/dL	1.05 ± 0.63	1.02 ± 0.85	0.648	1.15 ± 1.26	1.15 ± 1.19	0.956
Albumin, g/dL	4.15 ± 0.47	4.16 ± 0.47	0.692	4.12 ± 0.49	4.1 ± 0.53	0.426
INR	1.13 ± 0.26	1.12 ± 0.14	0.364	1.13 ± 0.21	1.14 ± 0.16	0.625
eGFR, mL/min/1.73 m ²	92.4 ± 24.8	94.4 ± 27.3	0.239	88.9 ± 29.1	88.1 ± 41.5	0.689
Platelet, ×10 ³ /μL	151.3 ± 53.7	152.7 ± 55.0	0.699	144.6 ± 56.8	142.8 ± 56.3	0.574
AFP, ng/mL	21.2 ± 69.7	20.9 ± 68.7	0.953	21.2 ± 62.0	20.8 ± 63.4	0.923
Child-Pugh score	5.21 ± 0.56	5.17 ± 0.49	0.299	5.26 ± 0.66	5.3 ± 0.69	0.383

Comparison of HCC incidence between entecavir and tenofovir

FIB-4	3.31 ± 2.70	3.15 ± 2.88	0.373	3.77 ± 3.55	4.04 ± 4.62	0.247
APRI	1.74 ± 3.03	1.64 ± 3.22	0.635	1.98 ± 3.52	2.4 ± 5.17	0.102

AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.

Table S8. Baseline characteristics of patients enrolled after 2011 adjusted by propensity score matching or inverse probability of treatment weighting

Variables	Propensity score matching			Inverse probability of treatment weighting		
	Entecavir n = 466	TDF n = 466	p value	Entecavir n = 595	TDF n = 567	p value
Age (year)	55.1 ± 11.7	54.6 ± 12.9	0.557	55.0 ± 12.0	55.3 ± 12.9	0.608
Sex, male	342 (73.4%)	341 (73.2%)	0.941	72.9%	72.8%	0.969
HBeAg-positive status	102 (21.9%)	104 (22.3%)	0.875	22.8%	22.4%	0.864
Decompensation status	54 (11.6%)	52 (11.2%)	0.837	17.3%	13.4%	0.065
NA-naïve	417 (89.5%)	405 (86.9%)	0.223	86.8%	87.5%	0.719
Diabetes mellitus, yes	86 (18.5%)	81 (17.4%)	0.669	20.0%	20.3%	0.912
Hypertension, yes	121 (26.0%)	115 (24.7%)	0.651	26%	25.9%	0.995
HBV DNA, log ₁₀ IU/mL	5.43 ± 1.42	5.41 ± 1.42	0.793	5.51 ± 1.45	5.35 ± 1.43	0.063
AST, U/L	105.6 ± 203.9	106.4 ± 249.7	0.953	132.5 ± 292.9	124.8 ± 276.7	0.641
ALT, U/L	130.0 ± 255.8	133.7 ± 332.2	0.846	168.1 ± 415.2	146.5 ± 340.8	0.331
Total bilirubin, mg/dL	1.66 ± 2.95	1.51 ± 2.63	0.412	1.75 ± 2.94	1.69 ± 3.04	0.719
Albumin, g/dL	4.04 ± 0.62	4.06 ± 0.57	0.592	3.99 ± 0.65	3.99 ± 0.62	0.861
INR	1.18 ± 0.28	1.16 ± 0.23	0.283	1.18 ± 0.25	1.19 ± 0.27	0.634
eGFR, mL/min/1.73 m ²	90.6 ± 27.1	93.1 ± 28.4	0.169	91.1 ± 31.7	90.8 ± 44.1	0.869
Platelet, ×10 ³ /μL	143.6 ± 55.2	146.9 ± 55.1	0.364	144.1 ± 57.6	142.6 ± 57.5	0.666
AFP, ng/mL	30.5 ± 144.1	30.8 ± 113.8	0.980	33.9 ± 155.0	33.9 ± 117.2	0.993
Child-Pugh score	5.61 ± 1.37	5.51 ± 1.21	0.288	5.77 ± 1.48	5.66 ± 1.44	0.219
FIB-4	4.03 ± 4.13	3.79 ± 3.94	0.367	4.31 ± 4.45	4.47 ± 5.22	0.569
APRI	2.53 ± 5.94	2.51 ± 6.52	0.963	2.96 ± 6.32	3.08 ± 7.27	0.761

AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.

Table S9. Comparison of baseline characteristics of patient subgroups (n = 1560)

Variables	Subgroup 1	Subgroup 2	Subgroup 3	p value	p value	p value
	n = 398	n = 595	n = 567	1 vs. 2	1 vs. 3	2 vs. 3
Age (year)	54.57 ± 11.5	55.89 ± 11.77	54.53 ± 12.9	0.081	0.952	0.060
Sex, male	305 (76.6%)	416 (69.9%)	428 (75.5%)	0.020	0.681	0.033
HBeAg-positive status	87 (21.9%)	122 (20.5%)	130 (23%)	0.608	0.685	0.309
Decompensation status	70 (17.6%)	112 (18.8%)	58 (10.2%)	0.622	< 0.001	< 0.001
NA-naïve	339 (85.2%)	536 (90.1%)	478 (84.3%)	0.019	0.711	0.003
Diabetes mellitus, yes	89 (22.4%)	143 (24%)	89 (15.7%)	0.542	0.009	< 0.001
Hypertension, yes	104 (26.1%)	176 (29.6%)	131 (23.1%)	0.236	0.281	0.012
HBV DNA, log ₁₀ IU/mL	5.30 ± 1.54	5.50 ± 1.46	5.37 ± 1.44	0.040	0.466	0.133
AST, U/L	128.1 ± 229.8	110.3 ± 203.2	113.1 ± 262.9	0.212	0.350	0.837
ALT, U/L	158.9 ± 305.9	125.9 ± 239.7	151.7 ± 386.1	0.070	0.748	0.173
Total bilirubin, mg/dL	2.29 ± 4.38	1.87 ± 3.43	1.57 ± 2.86	0.107	0.004	0.103
Albumin, g/dL	3.88 ± 0.60	3.92 ± 0.68	4.07 ± 0.57	0.290	< 0.001	< 0.001

Comparison of HCC incidence between entecavir and tenofovir

INR	1.21 ± 0.28	1.19 ± 0.27	1.17 ± 0.24	0.313	0.013	0.090
eGFR, mL/min/1.73 m ²	85.25 ± 29.51	85.5 ± 30.21	98.04 ± 52.24	0.894	< 0.001	< 0.001
Platelet, ×10 ³ /μL	122.7 ± 53.56	136.7 ± 56.52	150.4 ± 57.07	< 0.001	< 0.001	< 0.001
AFP, ng/mL	29.11 ± 83.72	33.9 ± 136.8	31.61 ± 113.8	0.494	0.694	0.756
Child-Pugh score	5.92 ± 1.61	5.88 ± 1.60	5.49 ± 1.19	0.690	< 0.001	< 0.001
FIB-4	5.57 ± 5.77	4.83 ± 5.17	3.69 ± 3.86	0.040	< 0.001	< 0.001
APRI	3.59 ± 6.87	2.89 ± 6.09	2.59 ± 6.55	0.102	0.023	0.421

Subgroup 1: patients treated with entecavir before 2011; subgroup 2: patients treated with entecavir after 2011; subgroup 3: patients treated with TDF. AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.

Table S10. Comparison of baseline characteristics of patient subgroups with compensated cirrhosis (*n* = 1320)

Variables	Subgroup 1 <i>n</i> = 328	Subgroup 2 <i>n</i> = 483	Subgroup 3 <i>n</i> = 509	<i>p</i> value 1 vs. 2	<i>p</i> value 1 vs. 3	<i>p</i> value 2 vs. 3
Age (year)	54.78 ± 11.43	56.02 ± 11.56	55.09 ± 13.03	0.133	0.724	0.230
Sex, male	254 (77.4%)	335 (69.4%)	375 (73.7%)	0.011	0.218	0.132
HBeAg-positive status	71 (21.6%)	106 (21.9%)	112 (22%)	0.919	0.891	0.969
NA-naïve	283 (86.3%)	436 (90.3%)	434 (85.3%)	0.079	0.682	0.016
Diabetes mellitus, yes	67 (20.4%)	118 (24.4%)	79 (15.5%)	0.182	0.0680	< 0.001
Hypertension, yes	84 (25.6%)	148 (30.6%)	120 (23.6%)	0.120	0.503	0.012
HBV DNA, log ₁₀ IU/mL	5.31 ± 1.50	5.51 ± 1.41	5.35 ± 1.43	0.060	0.693	0.088
AST, U/L	95.83 ± 170.0	85.95 ± 149.9	74.57 ± 127.7	0.3950	0.053	0.200
ALT, U/L	124.9 ± 203.9	100.4 ± 152.9	103.0 ± 241.0	0.065	0.158	0.841
Total bilirubin, mg/dL	1.32 ± 1.71	1.15 ± 1.4	1.01 ± 0.83	0.132	0.003	0.068
Albumin, g/dL	4.05 ± 0.46	4.12 ± 0.52	4.17 ± 0.47	0.054	< 0.001	0.102
INR	1.15 ± 0.22	1.14 ± 0.23	1.12 ± 0.17	0.505	0.078	0.270
eGFR, mL/min/1.73 m ²	83.88 ± 28.5	84.92 ± 27.74	97.23 ± 51.34	0.605	< 0.001	< 0.001
Platelet, ×10 ³ /μL	127.35 ± 54.1	143.38 ± 53.27	155.16 ± 55.98	< 0.001	< 0.001	< 0.001
AFP, ng/mL	20.99 ± 60.48	22.86 ± 63.52	20.81 ± 68.54	0.675	0.968	0.625
Child-Pugh score	5.33 ± 0.69	5.28 ± 0.73	5.17 ± 0.5	0.301	0.003	0.007
FIB-4	4.73 ± 4.91	3.77 ± 3.25	3.11 ± 2.83	0.002	< 0.001	0.001
APRI	2.64 ± 4.74	1.94 ± 3.5	1.61 ± 3.14	0.023	< 0.001	0.117

Subgroup 1: patients treated with entecavir before 2011; subgroup 2: patients treated with entecavir after 2011; subgroup 3: patients treated with TDF. AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.